{"title":"Effect of edible marine seaweeds on plasma glucose in healthy, at-risk, and type-2 diabetic individuals: a systematic review protocol.","authors":"Pratishtha Jain, Lokesh Ravi, Denny John","doi":"10.11124/JBIES-24-00388","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This review will investigate the effect of edible marine seaweeds on plasma glucose in healthy, at-risk, and type-2 diabetic individuals.</p><p><strong>Introduction: </strong>Edible marine seaweed has potential as a dietary supplement for individuals with varying glycemic status, including healthy individuals, those at risk of diabetes, and patients with diabetes. Systematic reviews on brown seaweeds do exist; however, a comprehensive review of marine seaweeds (brown, red, and green) is yet to be conducted.</p><p><strong>Inclusion criteria: </strong>This review will include studies comparing edible marine seaweed and/or seaweed extracts; either alone or in combination with other interventions; regardless of dosage, frequency, or duration; among adults 18 years or above; with placebo or any other treatments using other edible marine seaweeds; or the same treatment with different treatment doses in the intervention group.</p><p><strong>Methods: </strong>The review will follow the JBI methodology for systematic reviews of effectiveness. We will search PubMed, Embase (Ovid), Cochrane Central Register of Controlled Trials, CINAHL, Scopus, and Web of Science Core Collection for published studies. For unpublished literature, we will search ClinicalTrials.gov, WHO International Clinical Trials Registry, MedNar, ProQuest Dissertations and Theses, and Google Scholar. Titles, abstracts, and full-text papers will be assessed against the inclusion criteria by 2 independent reviewers. Selected studies will be critically appraised using the standardized JBI appraisal tools. Data will then be extracted, followed by meta-analysis or network meta-analysis for all outcomes. Weighted mean differences will be used for continuous data, while risk ratios will be used for dichotomous data. Certainty will be assessed using the GRADE approach.</p><p><strong>Review registration: </strong>PROSPERO CRD42024572994.</p>","PeriodicalId":36399,"journal":{"name":"JBI evidence synthesis","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI evidence synthesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBIES-24-00388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This review will investigate the effect of edible marine seaweeds on plasma glucose in healthy, at-risk, and type-2 diabetic individuals.
Introduction: Edible marine seaweed has potential as a dietary supplement for individuals with varying glycemic status, including healthy individuals, those at risk of diabetes, and patients with diabetes. Systematic reviews on brown seaweeds do exist; however, a comprehensive review of marine seaweeds (brown, red, and green) is yet to be conducted.
Inclusion criteria: This review will include studies comparing edible marine seaweed and/or seaweed extracts; either alone or in combination with other interventions; regardless of dosage, frequency, or duration; among adults 18 years or above; with placebo or any other treatments using other edible marine seaweeds; or the same treatment with different treatment doses in the intervention group.
Methods: The review will follow the JBI methodology for systematic reviews of effectiveness. We will search PubMed, Embase (Ovid), Cochrane Central Register of Controlled Trials, CINAHL, Scopus, and Web of Science Core Collection for published studies. For unpublished literature, we will search ClinicalTrials.gov, WHO International Clinical Trials Registry, MedNar, ProQuest Dissertations and Theses, and Google Scholar. Titles, abstracts, and full-text papers will be assessed against the inclusion criteria by 2 independent reviewers. Selected studies will be critically appraised using the standardized JBI appraisal tools. Data will then be extracted, followed by meta-analysis or network meta-analysis for all outcomes. Weighted mean differences will be used for continuous data, while risk ratios will be used for dichotomous data. Certainty will be assessed using the GRADE approach.
目的：探讨食用海藻对健康、高危和2型糖尿病患者血糖的影响。简介：可食用海藻有潜力作为不同血糖状态个体的膳食补充剂，包括健康个体、糖尿病风险人群和糖尿病患者。对褐藻的系统评价确实存在；然而，对海洋海藻（棕色、红色和绿色）的全面审查尚未进行。纳入标准：本综述将包括比较食用海藻和/或海藻提取物的研究；单独或与其他干预措施结合使用；不论剂量、频率或持续时间；18岁或以上成人；服用安慰剂或任何其他使用其他可食用海草的治疗；或者在干预组中使用不同剂量的相同治疗。方法：本综述将遵循JBI方法对有效性进行系统评价。我们将检索PubMed， Embase (Ovid), Cochrane Central Register of Controlled Trials， CINAHL， Scopus和Web of Science Core Collection以获取已发表的研究。对于未发表的文献，我们将检索ClinicalTrials.gov、WHO International ClinicalTrials Registry、MedNar、ProQuest博士论文和论文以及谷歌Scholar。题目、摘要和全文论文将由2名独立审稿人根据纳入标准进行评估。选定的研究将使用标准化的JBI评估工具进行严格评估。然后提取数据，对所有结果进行荟萃分析或网络荟萃分析。对于连续数据将使用加权平均差值，而对于二分类数据将使用风险比。将使用GRADE方法评估确定性。审核注册：PROSPERO CRD42024572994。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
